ArticleTherapeutic advances in chronic disease2011
Pegylated interferon and ribavirin treatment for hepatitis C virus infection.
Article in Therapeutic advances in chronic disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2022Pooled it
- Time required to achieve optimum viral load suppression with Ravidasvir/sofosbuvir in chronic hepatitis C patients with or without compensated cirrhosis.Scientific reports · 2025Trial
- Article
- A Novel Host-Based Immunotherapy for the Suppression of HBV and HCV Replication: Heat-KilledCells · 2026Article
- Epidemiology and control of hepatitis C virus infection in Brunei Darussalam: a retrospective cohort study.IJID regions · 2026Article
- Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.Cureus · 2024Review
- Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure.Clinical and experimental hepatology · 2023Article
- Viral proteases as therapeutic targets.Molecular aspects of medicine · 2022Review
- Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018.BMC infectious diseases · 2022Article
- Genome-wide association analyses of common infections in a large practice-based biobank.BMC genomics · 2022Article
- Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins fromMolecules (Basel, Switzerland) · 2022Article
- Viral Hepatitis - The Road Traveled and the Journey Remaining.Hepatic medicine : evidence and research · 2022Review
- A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.Gastroenterology research · 2021Review
- Article
- Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.World journal of gastroenterology · 2021Review
- Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV-HCV Coinfected Patients.Frontiers in molecular biosciences · 2021Article
- Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.International journal of molecular sciences · 2019Article
- Review
- Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.Journal of managed care & specialty pharmacy · 2019Article
- Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.Harm reduction journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients affected by chronic hepatitis C (CHC) infection, viral eradication can be achieved by antiviral therapy based on the use of a combination of pegylated interferon α-2a or 2b and ribavirin that yields a sustained eradication in 40-50% of cases. The aim of this review is to evaluate the efficacy of pegylated interferon α-2a or α-2b plus ribavirin in the treatment of CHC infection. Treatment must be started in patients with detectable serum hepatitis C virus (HCV) RNA independently by serum alanine aminotransferase levels. In patients infected with genotype 1 or 4 HCV before treatment, a histological evaluation is required. These patients can be treated if stage is ≥2 according to the Knodell index. The treatment must be for 1 year duration and current guidelines allow treatment to be continued if patients remain HCV RNA positive at week 12 if a 2-log drop in viral load has been achieved. In patients with genotype 2 or 3 HCV, therapy must be prolonged for 6 months and histological evaluation pretreatment is not necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.